Antitelomerase, adjuvant, neoadjuvant, breast cancer, chemotherapy
Biology | Cancer Biology | Cell Biology | Medicine and Health Sciences
Pardy, Luke T., "Effect of Adjuvant and Neoadjuvant Anti-telomerase with Anthracycline based Chemotherapy on Triple Negative Breast Cancer Cells" (2015). Student Summer Scholars. 147.
Breast cancer is the second leading cause of cancer related death in women in the US. In addition, 20% of all breast cancer cases in the U.S. are from the subtype known as Triple-Negative Breast Cancer (TNBC), which is the most aggressive and invasive form of the disease. This type of breast cancer has the worst prognosis, a decreased survival rate, and no targeted therapy. Over the decades, interest in pre- (Neoadjuvant) and post- (Adjuvant) chemotherapy treatments, in the management of TNBC has increased. Therefore, we evaluated the Adjuvant and Neoadjuvant effects of anti-telomerases (BIBR 1532 and GV6) with anthracycline-based (Doxorubicin) chemotherapy. In the initial (Neoadjuvant) experiment, MDA-MB-231 (TNBC) cells were supplemented with BIBR 1532 (n=4) or GV6 (n=4-6) for 14 days, then exposed to Doxorubicin (n=4) for 7 days. In the second (Adjuvant) experiment, cells were primed with Doxorubicin for 7 days (n=4) prior to 14 days of BIBR 1532 (n=4) or GV6 (n=4) therapy. The Trypan Blue (Gibco) exclusion test was used to assess the viability of the cells. After 14 days of Neoadjuvant treatment with BIBR1532, followed by 7 days of doxorubicin treatment, the cell density decreased to 59% of control (p<0.05). Adjuvant treatment with BIBR 1532 or GV6 had limited effect on the proliferation rate of MDA-MB-231 cells. A higher (p<0.05) percent of dead cells was observed in BIBR1532 adjuvant therapy with doxorubicin. These data indicates that neoadjuvant therapy with anti-telomerase in conjunction with anthracycline-based chemotherapy does have beneficial effects and warrants further investigation.